You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Non-specific effects of BCG

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-specific Effects of BCG in Under-five Children

Active, not recruiting
  • Immunity, Heterologous
  • BCG
  • Lisboa, Portugal
    Instituto de Higiene e Medicina Tropical
Jul 20, 2022

Death; Neonatal, Death, Infant, Morbidity;Newborn Trial in Bissau (BCG-Denmark, BCG-Bulgaria)

Not yet recruiting
  • Death; Neonatal
  • +4 more
  • BCG-Denmark
  • BCG-Bulgaria
  • Bissau, Guinea-Bissau
    Bandim Health Project
May 26, 2022

Vaccine Response Impaired Trial in Adelaide (BCG vaccine, Yellow Fever vaccine, Vancomycin Oral Capsule)

Recruiting
  • Vaccine Response Impaired
  • BCG vaccine
  • +3 more
  • Adelaide, South Australia, Australia
    South Australian Health and Medical Research Institute
Nov 17, 2023

Severe Illness, Septicaemia, Diarrhoea Trial in Kampala (BCG at birth, Control arm: Delayed BCG)

Recruiting
  • Severe Illness
  • +3 more
  • BCG at birth
  • Control arm: Delayed BCG
  • Kampala, Uganda
    Health Centers in Mukono and Kampala districts
Aug 24, 2022

Covid19, Non-specific Effects of Vaccines, Heterologous Immunity Trial in Odense (BCG-Denmark, Saline)

Active, not recruiting
  • Covid19
  • +5 more
  • BCG-Denmark
  • Saline
  • Odense, Denmark
    Seniorhuset
Feb 28, 2022

Vaccine Preventable Disease, Measles, Mother-Infant Interaction Trial in Bissau (BCG vaccine, Measles vaccine, Placebo)

Recruiting
  • Vaccine Preventable Disease
  • +3 more
  • BCG vaccine
  • +2 more
  • Bissau, Bissau Codex, Guinea-Bissau
    Bandim Health Project
May 23, 2021

Non-Muscle- Invasive Bladder Cancer Trial (Durvalumab, BCG)

Not yet recruiting
  • Non-Muscle- Invasive Bladder Cancer
  • Durvalumab
  • BCG
  • (no location specified)
Jul 5, 2023

Non-muscle-invasive Bladder Cancer Trial (Gemcitabine, Docetaxel, Bacillus Calmette Guerin)

Not yet recruiting
  • Non-muscle-invasive Bladder Cancer
  • (no location specified)
Sep 9, 2022

Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive

Recruiting
  • Non Muscle Invasive Bladder Cancer
  • N803 plus Bacillus Calmette-Guerin (BCG)
  • Honolulu, Hawaii
    Island Urology
Aug 7, 2023

Heterologous Immunity, Infant Morbidity, Infant Mortality Trial in Bissau (BCG-Japan, BCG-Russia)

Completed
  • Heterologous Immunity
  • +5 more
  • BCG-Japan
  • BCG-Russia
  • Bissau, Guinea-Bissau
  • +1 more
Dec 13, 2020

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

Non-muscular Invasive Bladder Cancer Trial in Changsha (BCG for therapeutic use)

Not yet recruiting
  • Non-muscular Invasive Bladder Cancer
  • BCG for therapeutic use
  • Changsha, China
    Hunan Cancer Hospital
Oct 20, 2023

Neutrophils to Lymphocytes Ratio in Predicting Response to BCG

Completed
  • Urinary Bladder Cancer
  • +4 more
  • Neutrophil to lymphocyte ratio
  • Cairo, Egypt
    Ain Shams university
Jul 15, 2023

Bladder Cancer Trial in Nara, Okayama (FE 999326)

Recruiting
  • Bladder Cancer
  • FE 999326
  • Nara, Japan
  • +1 more
Jan 19, 2023

Non-muscle-invasive Bladder Cancer Trial in Shanghai (BCG combined with Tislelizumab)

Not yet recruiting
  • Non-muscle-invasive Bladder Cancer
  • BCG combined with Tislelizumab
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Oct 12, 2022

Urothelial Carcinoma, Bladder Cancer Trial in United States (drug, radiation, biological)

Recruiting
  • Urothelial Carcinoma
  • Bladder Cancer
  • Durvalumab (Cohort 1-3)
  • +7 more
  • Phoenix, Arizona
  • +10 more
Jan 11, 2023

Non-muscle-invasive Bladder Cancer Trial in Zagreb (Gemcitabine 1000 mg, Docetaxel 37.5g)

Active, not recruiting
  • Non-muscle-invasive Bladder Cancer
  • Gemcitabine 1000 mg, Docetaxel 37.5g
  • Zagreb, Croatia
    University Hospital Centre Zagreb
Jan 20, 2023

Urinary Bladder Tumors Trial run by the NCI (Durvalumab, Vicineum)

Recruiting
  • Urinary Bladder Neoplasms
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Bladder Cancer, Bladder Cancer Recurrent, Tumor Recurrence Trial (Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus

Not yet recruiting
  • Bladder Cancer
  • +5 more
  • Bacillus Calmette-Guerin: Strain Russian BCG-I
  • Bacillus Calmette-Guerin: Strain TICE
  • (no location specified)
Apr 7, 2022

Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma Trial in Tampa (Adoptive Cell Therapy with Tumor-infiltrating

Recruiting
  • Urothelial Carcinoma
  • Non-Invasive Bladder Urothelial Carcinoma
  • Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
  • Tampa, Florida
    Moffitt Cancer Center
Mar 2, 2023

Non-Muscle Invasive Bladder Cancer Trial in Québec (Bicalutamide, Control Arm)

Recruiting
  • Non-Muscle Invasive Bladder Cancer
  • Québec, Canada
    CHU de Québec-Université Laval
Jul 13, 2022

Non-muscle-invasive Bladder Cancer Trial in Cairo (BCG, Gemcitabine)

Recruiting
  • Non-muscle-invasive Bladder Cancer
  • Cairo, Egypt
    Mohamed Fawzy Salman
Nov 19, 2022

Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma Trial in Chicago (BCG

Active, not recruiting
Has Results
  • Recurrent Bladder Carcinoma
  • +3 more
  • BCG Solution
  • +3 more
  • Chicago, Illinois
    Northwestern University
Sep 27, 2022

Non-Muscle Invasive Bladder Cancer Trial in Mansoura (Bacillus Calmette-Guerin)

Recruiting
  • Non-Muscle Invasive Bladder Cancer
  • Bacillus Calmette-Guerin
  • Mansoura, Outside U.S./Canada, Egypt
    Urology and Nephrology Center
Apr 11, 2022

High-risk NMIBC Trial (SHR-1501)

Recruiting
  • High-risk NMIBC
  • Beijing, Beijing, China
    Peking University First Hospital
Nov 28, 2022